Navigation Links
Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec
Date:10/31/2007

HAE: TSX

MONTREAL, Oct. 31 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE), a specialty bio-therapeutics company, announces the webcast of its presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference, on November 7, 2007 at 11:30 a.m. at the New York Palace Hotel in New York.

Rodman & Renshaw will webcast the audio portion of the presentation and post the associated slides via its website at http://www.rodmanandrenshaw.com, hosted by Wall Street Webcasting. To access the live broadcast via internet in listen-only mode, or the subsequently archived recording, please cut and paste the following link directly into your web browser:

http://www.wsw.com/webcast/rrshq12/hae.cn

Please visit the site at least five minutes prior to start time for instructions.

About the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

The Conference will include presentations by over 375 companies, as well as experts from the medical, scientific and investment communities. The Conference will be attended by investors, venture capitalists, company executives, scientists and other industry leaders. Since 1951, Rodman & Renshaw has been dedicated to serving the needs of companies in emerging growth sectors and the investors that seek value in these companies. The Acumen BioFin division of Rodman & Renshaw is exclusively focused on healthcare and life science companies. For further information, visit http://www.rodmanandrenshaw.com.

About Haemacure

Haemacure Corporation is a specialty bio-therapeutics company developing high-value human therapeutic proteins for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats.

Haemacure's lead product candidate, Hemaseel(R)HMN, is a human-derived fibrin sealant in late-stage clinical development. Haemacure's second product candidate is human thrombin, a component of its fibrin sealant. Both candidates have applications in the expanding bio-surgical market. Follow-on development will focus on surgical hemostats, biomaterial combinations and drug delivery in select therapeutic areas. Haemacure has recently discovered additional specialty proteins in its plasma-derived intermediates and will advance these specialty proteins through partnerships with other pharmaceutical and biotechnology companies.

Forward-looking Statements

Certain statements contained in this news release and oral statements made by representatives of Haemacure that are not historical facts may be considered forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure Corporation does business, stock market volatility, fluctuations in costs, the ability of Haemacure to set up its planned manufacturing facility, the completion and outcome of clinical studies as well as the development of new products, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure Corporation disclaims any intention or obligation to update these statements.


'/>"/>
SOURCE Haemacure Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Nursing Society (ONS) wanted to create a communications platform that positions them as ... goal, Elliance and ONS reinvented their online publication as an always-on, always-fresh news, ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation of ... college Bible teacher residing in North Carolina with his wife, Anna Marie. He and ... with six grandchildren. David is also the author of “Shadow and Substance.” , “Love, ...
(Date:3/23/2017)... ... ... The physicians of KSF Orthopaedic Center PA are proud to announce the ... located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside the ... living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with an ...
(Date:3/23/2017)... Holland, PA and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI ... the modular industry or whose acts have had a significant impact on the careers of ... Sales and Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... SAN DIEGO , March 24, 2017  GenomeDx ... (Genomics Resource Information Database) and Decipher® Prostate Cancer Classifier ... Annual European Association of Urology (EAU) Congress held March ... . The Annual EAU Congress is ... and most comprehensive research in the urological field. ...
(Date:3/24/2017)... BOTHELL, Wash. , March 23, 2017 /PRNewswire/ ... developer of advanced medical technology for non-invasive surgery, ... the Mirabilis System for treatment of uterine fibroids ... that it had received approval from the US ... study of the Mirabilis System in the United ...
(Date:3/24/2017)... The Board of Directors of Nordic Nanovector ASA ... the complete 2016 Annual Accounts with notes. The report is ... in the section Investor Relations/Reports and presentations/Annual Reports. ... For further information, ... Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com Media ...
Breaking Medicine Technology: